Opinion & analysis

J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven And Lilly

The second day of the 2019 JP Morgan Healthcare Conference has concluded, and Pink Sheet was there to bring you all of the breaking news, major announcements, and insights from the largest investment healthcare symposium in the world.

January 9, 2019

Find out more

Oncology Leader Liz Barrett Joins UroGen As CEO As It Heads Towards Commercial Stage

$131.00

There is new leadership at UroGen Pharma, Ltd., as Novartis AG Oncology’s former Oncology CEO takes the helm. Scrip sat down to talk to Liz Barrett about her plans as CEO of UroGen, including assuming the tasks of ushering the company’s lead asset through the FDA approval and launch processes.

January 9, 2019

Find out more

J.P. Morgan 2019: Industry Throws A Bonanza, With An Elephant In The Room

$200.00

Major deal news, exciting new scientific developments, and an atmosphere of bold enthusiasm masked concerns over US drug pricing and political worries at the 2019 J.P. Morgan Healthcare Conference in San Francisco. Scrip was there to report on what was discussed – and what wasn’t – at the largest pharma-industry business meeting of the year.

January 9, 2019

Find out more

J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven, Lilly And FDA’s Gottlieb

$200.00

Scrip reports from Day 2 of the 2019 J.P. Morgan Healthcare Conference, bringing you the highlights to come out of the San Francisco meeting. Read the most important news from Day 2, including the latest from Biogen, updates on GSK’s oncology efforts, deal developments for bluebird and Lilly, and more.

January 9, 2019

Find out more

Into 2019: Risk, Uncertainty And A Return To Product Focus

$200.00

ZS’ Brian Chapman’s five predictions for medtech in 2019 sound generally positive. Find out about what makes him optimistic–such as the use of real-world evidence to drive reimbursement discussions. Gain insights into why he’s concerned about the impact of geopolitical uncertainty.

January 9, 2019

Find out more

Herbalife Shakes Up Executive Suite Due To CEO’s Earlier Statements On Expenses

$131.00

Herbalife CEO Richard Goudis stepped down from the top spot at the company following the discovery of inappropriate comments he had made prior to becoming CEO. Find out more about the Herbalife shakeup and what it means for the company.

January 8, 2019

Find out more

J&J CEO Sees Victory Ahead On Talc, Growth From Johnson’s Relaunch

$200.00

For a view into where Johnson & Johnson stands now in the wake of both controversy over the safety of its talc products and the Johnson brand’s relaunch as a natural product line, tap into this article covering highlights of J&J’s remarks at the 2019 JP Morgan Healthcare Conference.

January 8, 2019

Find out more

The Next New Thing In FDA Inspections: Poor Root Cause Investigations

$131.00

As the pharmaceuticals industry gets its issues with data integrity under control, a new challenge has arisen, according to US FDA comments at a recent meeting of the International Society for Pharmaceutical Engineering. Find out how these out-of-specification investigation (OOS) issues are playing out, with expert reporting from Pink Sheet.

January 6, 2019

Find out more

Bristol-Myers, Celgene and The Perils Of The US Drug Pricing Environment

$131.00

Pink Sheet brings you a look at the effects of the Bristol-Celgene merger on the public and political perceptions of the companies, with an examination of how pricing for Revlimid has affected Celgene’s public image and stock pricing.

January 6, 2019

Find out more

Burt’s Bees Hopes Third Time’s A Charm For Toothpaste, This One With P&G

$131.00

Burt’s Bees is making another foray into the toothpaste category with a line for adults and children and a strategic licensing partnership with Procter & Gamble, makers of Crest. Discover the details of this third attempt to successfully enter the oral care space by the Clorox-owned Burt’s Bees.

January 5, 2019

Find out more

Germany Begins The Year With Two Possible Rx-To-OTC Switches

$131.00

During their bi-annual meeting, Germany’s Expert Committee for Prescription was set to discuss a move from prescription to OTC status for hydrocortisone 1% for external use, and combination ibuprofen and phenylephrine hydrochloride. Get the details of the proposal with reporting from HBW Insight.

January 4, 2019

Find out more

Brexit At The 11th Hour: UK Refreshes No-Deal Guidance For Medtech

$200.00

As Brexit looms and a no-deal scenario becomes increasingly a possibility, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has updated their guidance on how to respond should no deal with Europe be reached. What does it mean for Medtech? Find out here.

January 4, 2019

Find out more

Drug Firms Fear PBM ‘Discrimination’ Over List Price Reductions, Azar Tells Hearing

$131.00

Despite remarks from the US President to the contrary, US pharmaceutical companies have not yet voluntarily lowered their prices. Health and Human Services Secretary Alex Azar discusses the reasons why, and delves into the use of regulations as a means of prohibiting rebates in this illuminating article from Pink Sheet.

January 3, 2019

Find out more

The Case For CAR-T Grows As Responses Hold Up Longer Term

$200.00

Scrip speaks with Pascal Touchon, Senior Vice President and Global Head, Cell & Gene Therapy at Novartis AG about the company’s encouraging successes with CAR-T therapies, as evidenced by 18-month data released during the December 2018 meeting of the American Society of Hematology.

December 20, 2018

Find out more

Opinion & analysis

J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven And Lilly

Oncology Leader Liz Barrett Joins UroGen As CEO As It Heads Towards Commercial Stage

J.P. Morgan 2019: Industry Throws A Bonanza, With An Elephant In The Room

J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven, Lilly And FDA’s Gottlieb

Into 2019: Risk, Uncertainty And A Return To Product Focus

Herbalife Shakes Up Executive Suite Due To CEO’s Earlier Statements On Expenses

J&J CEO Sees Victory Ahead On Talc, Growth From Johnson’s Relaunch

The Next New Thing In FDA Inspections: Poor Root Cause Investigations

Bristol-Myers, Celgene and The Perils Of The US Drug Pricing Environment

Burt’s Bees Hopes Third Time’s A Charm For Toothpaste, This One With P&G

Germany Begins The Year With Two Possible Rx-To-OTC Switches

Brexit At The 11th Hour: UK Refreshes No-Deal Guidance For Medtech

Drug Firms Fear PBM ‘Discrimination’ Over List Price Reductions, Azar Tells Hearing

Top 10 Most Read Stories Of 2018

The Case For CAR-T Grows As Responses Hold Up Longer Term